Results 181 to 190 of about 180,170 (299)

Where Is the 'Oma' in Multiple Myeloma? Origins and Limitations of some Myeloma-Related Terminology. [PDF]

EJHaem
Thachil J, Steensma DP.
europepmc   +1 more source

MajesTEC-3: Redefining what's possible in multiple myeloma. [PDF]

Clin Hematol Int
Al Hadidi S, Gaballa M.
europepmc   +1 more source

Multiple myeloma

HemaSphere, 2019
openaire   +4 more sources

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium. [PDF]

Blood Cancer J
Portuguese AJ, Davis JA, Raza S, Castaneda Puglianini O, Freeman C, Alsina M, Wright C, Blue BJ, Baz RC, Shain KH, Goel U, Khouri J, Anwer F, Ali HM, Pasvolsky O, Gaballa M, Patel K, Garcia-Pleitez H, Mikulski D, Fogel L, Zolotov E, Sannareddy A, Afrough A, Anderson LD, Julian K, Dima D, Banerjee R, Liang EC, Cassano Cassano R, Herr MM, Hassan H, Shune L, Kort J, Midha S, Nadeem O, Sidana S, Lin Y, Locke FL, Hansen DK, Sborov D, Biran N, Grajales-Cruz A.   +41 more
europepmc   +1 more source

Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial

British Journal of Haematology, EarlyView.
Summary There is an ongoing need for accessible combination therapies for patients with relapsed‐refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T‐cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open‐label ...
Andrew Hall, James Croft, Katrina Walker, Kevin Boyd, Sadie Roberts, Amy Holroyd, Mamta Garg, Elsa Ferris, Gordon Cook, William E. Pierceall, Anjan Thakurta, Anita Gandhi, Charlotte Pawlyn, Sarah R. Brown, Martin Kaiser   +14 more
wiley   +1 more source

MRD in multiple myeloma: the clinical perspective. [PDF]

Front Oncol
Caravita di Toritto T, Rago A.
europepmc   +1 more source

Insulin Signalling-Inducible IFITM1 Promotes Multiple Myeloma Progression and Bortezomib Resistance. [PDF]

J Cell Mol Med
Lim JY, Kim Y, Park SS, Lee J, Min CK.
europepmc   +1 more source

Diagnosis and management of neutropenia in adults: Expert guidance

British Journal of Haematology, EarlyView.
Severe neutropenia can result from decreased production of neutrophil precursors in the bone marrow, as in the case of severe congenital neutropenia, or from increased utilization of neutrophils or their accelerated destruction as for drug‐induced neutropenia or autoimmune neutropenia. Severe chronic neutropenia increases susceptibility to bacterial or
Karl Welte, Cornelia Zeidler, Julia Skokowa, Sabine Mellor‐Heineke, Audrey Anna Bolyard, David Dale   +5 more
wiley   +1 more source

Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention. [PDF]

Cancer Res Commun
Feldman K, Li H, Basali D, Anwer F, Bell K, Faiman B, Jackson RD, Mazzoni S, Moore K, Patel N, Raza S, Valent J, Hurwitz HM.   +12 more
europepmc   +1 more source

Multifactorial Torsades de Pointes in a Multiple Myeloma Patient. [PDF]

JACC Case Rep
Tanousian A, Campeanu IJ, Reddy BH.
europepmc   +1 more source